Navigation Links
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Date:10/25/2012

OSAKA, Japan, October 25, 2012 /PRNewswire/ --

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization Application (MAA) for an atypical antipsychotic medication lurasidone hydrochloride for the treatment of schizophrenia. The MAA was filed by Takeda Global Research & Development Centre (Europe).

Lurasidone, orally administrated once daily, is an atypical antipsychotic medication discovered and developed by DSP with a unique chemical structure as compared to other existing antipsychotic medicines. Takeda entered into a license agreement with DSP stipulating the joint development and grant of an exclusive commercialization right of the product to Takeda in 26 member states of the European Union (excluding the United Kingdom), and Switzerland, Norway, Turkey and Russia in March 2011.

The MAA submission is based on the data from more than 50 clinical trials involving more than 3,800 lurasidone-treated subjects. In phase 3 clinical trials, in which the efficacy and safety of lurasidone in the treatment of patients with schizophrenia were evaluated, lurasidone demonstrated significantly greater improvement versus placebo in the primary efficacy endpoint [Positive and Negative Syndrome Scale (PANSS)* total score]. The most commonly observed adverse reactions in patients treated with lurasidone were somnolence, akathisia, nausea and parkinsonism. Clinical trials also demonstrated that lurasidone was well-tolerated with minimal impact on weight or metabolic parameters.

"Lurasidone is the DSP Group's core product for overseas expansion, and I am very pleased that we have achieved the important milestone of submitting an MAA in Europe." said Masayo Tada, President and Chief Executive Officer of DSP. "Through the cooper
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014   Veracyte, Inc. (Nasdaq: ... , president and chief executive officer, will present in a ... Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 ... The live audio webcast and subsequent replay may be ... connect to the website at least 15 minutes prior to ...
(Date:11/24/2014)... The new video, “ Save ... demonstrates how to reduce the number of instruments ... panel design can be complicated, requiring multiple chemical ... corrosion and deposition. Dedicated single and dual channel ... panel space. Additionally, installing and maintaining each transmitter, ...
(Date:11/22/2014)... Audubon, PA and London (PRWEB) November 21, 2014 ... in December will explore what comes next for ALS research ... clinical sites. , After the Ice Bucket Challenge: Where ... Merit Cudkowicz, Date: Tuesday, 2 December 2014, Time: ... complimentary , Join expert speaker Dr. Merit Cudkowicz, Julianne ...
(Date:11/22/2014)... MD (PRWEB) November 21, 2014 ... management solutions provider, has released Limfinity® version 5.1.4. ... installation projects of Limfinity® than ever in RURO’s ... configuration and minority framework enhancement. Limfinity® version 5.1.4 ... far above and beyond bug fixes! , Limfinity® ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2RURO Announces Limfinity® version 5.1.4 2
... Among top 10 most promising drugs ... TSX ... Corp,s,("Resverlogix" or the "Company") (TSX:RVX) novel lead ApoA-I drug,candidate, RVX-208 ... promising,cardiovascular disease (CVD) drugs available for strategic partnering by an,independent ...
... Calif., July 9 Cepheid (Nasdaq:,CPHD) today ... expert on Healthcare Associated Infections, Fred Tenover, ... Tenover will serve as a liaison,with the ... Healthcare,Associated Infection (HAI) Consortium program., "The ...
... TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics ... "Corporation"), a biopharmaceutical company,specializing in the research ... the management of cancer, today announced progress ... publication of two,research studies on the Virulizin(R) ...
Cached Biology Technology:Industry Leaders Select Resverlogix's RVX-208 2Industry Leaders Select Resverlogix's RVX-208 3Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
(Date:11/4/2014)... death at the right time might actually help boost ... could help in understanding animal populations, pest control and ... in the journal Trends in Ecology and Evolution ... that the kind of positive population effect an overall ... depends on the size and developmental stage of the ...
(Date:11/4/2014)... research study examining only marketing directed at children ... restaurants has found that the majority of black, ... such marketing tactics. , Authored by Arizona State ... study is the first to examine the use ... of fast food restaurants and its relationship to ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2When less is more: Death in moderation boosts population density in nature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... neural cell types are essential for studies of ... Neural Cells: A Laboratory Manual provides step-by-step protocols ... and culturing them under conditions that closely resemble ... how to dissect the brain, spinal cord, and ...
... of students and faculty at Grand Valley State University have ... to further a growing medical field that aims to improve ... four Grand Valley students and graduates, and Anthony Chang from ... Molecular Imaging Congress, one of the largest meetings in the ...
... news release is available in German . ... the basic principles of movement in the cellular cosmos. However, up ... several of these small cellular appendages are synchronised. Dresden-based researchers from ... the MPI for the Physics of Complex Systems have now succeeded ...
Cached Biology News:GVSU students contribute to growing medical field 2Green algae move to the beat 2
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
... Object Parametric Analyzer and Sorter) large particle ... advantages of flow cytometry to applications that ... automated analysis and sorting. Our instruments ... traditional flow cytometers, but are designed to ...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
... polyclonal antibody raised against a ... Immunogen: SF3B2 (NP_006833, ... partial recombinant protein with GST ... Number: NM_006842 ...
Biology Products: